Fig. 5.

Effect of 1D11 on TMV classification (turnover, mineralization and volume) and cortical bone resorption. 8 week old jck mice were treated with 1D11 as described in the “Methods” and Fig 3. (A) 1D11 dose-dependently suppresses bone formation rate (BFR/BS) after 7 weeks of treatment. (B) 1D11 has no impact on bone mineralization measured by mineralization lag time (MLT). (C) 1D11 increases BV/TV (%) after 4 weeks at 5 mg/kg dose and after 7 week treatment at both 2 and 5 mg/kg doses. Results are expressed as mean ± SEM. * indicates p < 0.05 compared with age-matched jck mice treated with PBS by one-way ANOVA and Tukey’s multiple comparison test (n ≥ 12 in the 4 week treatment groups; n ≥ 8 in the 7 week treatment groups). (D) Representative H&E and TRAP stained sections from femurs showing 1D11 reduces cortical bone resorption (porosity, black arrow). (E) semi-quantitative scores of cortical bone resorption shows a trend toward decreased cortical porosity.